• Sino Biopharmaceutical’s unit LaNova Medicines secured NMPA clearance to start China trials of LM-364, a Nectin-4 TME-responsive ADC.
• The FDA granted US clinical trial authorization in April; the program has already begun dosing in Australia.
• The study targets advanced solid tumors, evaluating safety, tolerability, pharmacokinetics, early efficacy, combination potential, and a recommended dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304112), on August 28, 2026, and is solely responsible for the information contained therein.